What is Transcend?
Operating under the umbrella of Somnetics International, Inc., Transcend has established itself as an emerging leader in the design, development, and production of innovative respiratory medical devices. The company is primarily focused on addressing the needs of patients suffering from sleep apnea, leveraging customer-driven design to create high-quality, portable CPAP solutions. With accolades such as the Medtrade Innovation Award and Frost & Sullivan's Best Practices Award, the company has demonstrated a consistent ability to differentiate its product offerings in a crowded market. The recent FDA clearance and CE Mark for its flagship Transcend 365 CPAP machine underscore the company's commitment to regulatory excellence and international market accessibility.
How much funding has Transcend raised?
Transcend has raised a total of $933K across 2 funding rounds:
Debt
$350K
Debt
$583K
Debt (2020): $350K with participation from PPP
Debt (2021): $583K led by PPP
Key Investors in Transcend
PPP
Public-Private Partnership
What's next for Transcend?
With the recent strategic investment, Transcend is poised to enter a new phase of enterprise-level scaling. The company is expected to prioritize the expansion of its manufacturing capabilities and the enhancement of its digital health integration, ensuring that its respiratory devices remain at the forefront of patient-centric care. Future initiatives will likely focus on deepening market penetration in both domestic and international territories, while simultaneously investing in research and development to address emerging challenges in sleep-disordered breathing. By maintaining its focus on technological innovation and high-quality production, Transcend is strategically aligned to capture a larger share of the growing respiratory health market, ultimately improving patient outcomes through advanced, portable medical technology.
See full Transcend company page
